Norvasc: Effective Blood Pressure Control with Amlodipine
Norvasc
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.83 | $50.00 (0%) | 🛒 Add to cart |
| 90 | $0.77 | $75.00 $69.00 (8%) | 🛒 Add to cart |
| 120 | $0.72 | $100.00 $87.00 (13%) | 🛒 Add to cart |
| 180 | $0.68 | $150.00 $123.00 (18%) | 🛒 Add to cart |
| 270 | $0.66 | $225.00 $177.00 (21%) | 🛒 Add to cart |
| 360 | $0.64
Best per pill | $300.00 $232.00 (23%) | 🛒 Add to cart |
| Product dosage: 2.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 180 | $0.34 | $61.00 (0%) | 🛒 Add to cart |
| 270 | $0.31 | $91.50 $85.00 (7%) | 🛒 Add to cart |
| 360 | $0.30
Best per pill | $122.00 $109.00 (11%) | 🛒 Add to cart |
Norvasc (amlodipine besylate) is a first-line prescription medication belonging to the calcium channel blocker class, specifically indicated for the treatment of hypertension and chronic stable angina. It functions by selectively inhibiting the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, resulting in peripheral arterial vasodilation and reduced afterload. This mechanism of action provides a predictable and sustained antihypertensive and antianginal effect, making it a cornerstone therapy in cardiovascular management. Its favorable pharmacokinetic profile, characterized by a long half-life, supports once-daily dosing, which enhances patient adherence and provides 24-hour therapeutic coverage.
Features
- Active Pharmaceutical Ingredient: Amlodipine besylate
- Therapeutic Class: Dihydropyridine calcium channel blocker (CCB)
- Standard Available Strengths: 2.5 mg, 5 mg, and 10 mg oral tablets
- Dosing Regimen: Typically administered once daily
- Onset of Action: Gradual, with peak plasma concentrations occurring between 6 and 12 hours post-administration
- Elimination Half-Life: Approximately 30-50 hours, supporting stable plasma levels
- Bioavailability: Estimated at 64-90% following oral administration
Benefits
- Provides consistent 24-hour blood pressure control with a single daily dose, reducing blood pressure variability.
- Effectively reduces myocardial oxygen demand by decreasing peripheral vascular resistance and afterload, alleviating angina symptoms.
- Demonstrates a gradual onset of action, minimizing the risk of reflex tachycardia and other acute hemodynamic disturbances.
- Offers a well-established safety and efficacy profile supported by extensive clinical trial data and decades of real-world use.
- Can be used as monotherapy or effectively combined with other antihypertensive agents like ACE inhibitors or thiazide diuretics.
Common use
Norvasc is primarily indicated for two conditions. First, for the management of hypertension, either as monotherapy or in combination with other antihypertensive agents, to lower elevated blood pressure and reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Second, for the treatment of chronic stable angina and vasospastic (Prinzmetal’s or variant) angina. It is used to reduce the frequency of angina attacks and decrease the need for sublingual nitroglycerin, improving exercise tolerance. It is not indicated for the acute relief of an angina attack.
Dosage and direction
Dosage must be individualized based on therapeutic goals and patient response. For hypertension, the usual initial adult dose is 5 mg taken orally once daily. The dosage may be increased to a maximum dose of 10 mg once daily, with adjustments typically made over 7-14 day intervals. Small, fragile, or elderly patients, or patients with hepatic insufficiency, may be started on 2.5 mg once daily as an initial dose. For angina, the usual recommended dose is 5–10 mg, with the lower 5 mg dose suggested for the elderly and patients with hepatic impairment. Norvasc may be administered with or without food. Tablets should be swallowed whole with a glass of water. Consistency in the time of daily administration is recommended to maintain stable plasma concentrations.
Precautions
Patients should be monitored for the development of hypotension, particularly in those with severe aortic stenosis. Due to its mechanism of vasodilation, cautious use is advised in patients with heart failure, as the drug may have a negative inotropic effect, though this is less common with dihydropyridines like amlodipine. Close observation is recommended when initiating therapy in patients awaiting coronary artery bypass surgery (CABG). Patients with severe obstructive coronary artery disease may, in rare instances, experience increased frequency, duration, or severity of angina or acute myocardial infarction upon starting calcium channel blocker therapy or at the time of dosage increase. Patients with hepatic impairment will have increased systemic exposure to amlodipine and require dose adjustments and careful titration.
Contraindications
Norvasc is contraindicated in patients with known hypersensitivity to amlodipine or any other dihydropyridine derivatives, or to any of the inactive ingredients in the formulation. Its use is also contraindicated in patients with cardiogenic shock, clinically significant aortic stenosis, or unstable angina (outside a chronic stable angina indication) unless concurrently managed with appropriate anti-ischemic therapy. The safety and efficacy of Norvasc in children have not been established.
Possible side effect
The most common side effects are related to its vasodilatory effects and are usually dose-dependent. These include:
- Very Common (>1/10): Peripheral edema (swelling of the ankles and feet), headache, flushing.
- Common (1/10 to 1/100): Dizziness, palpitations, fatigue, nausea, abdominal pain, somnolence.
- Uncommon (1/100 to 1/1000): Dyspnea, muscle cramps, asthenia, pruritus, rash, dyspepsia, gingival hyperplasia, mood changes.
- Rare (<1/1000): Hepatitis, jaundice, increased frequency of micturition. Serious side effects are uncommon but can include severe hypotension, arrhythmias, and myocardial infarction. Patients should be instructed to report any signs of an allergic reaction, pronounced dizziness, fainting, swelling that worsens, or significant weight gain.
Drug interaction
Norvasc is primarily metabolized by the CYP3A4 enzyme system. Concomitant use warrants caution with:
- Strong CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin): May significantly increase amlodipine plasma concentrations, increasing the risk of adverse effects like hypotension and edema. Dose adjustment may be necessary.
- Moderate CYP3A4 Inhibitors (e.g., diltiazem, erythromycin, fluconazole): May increase amlodipine systemic exposure. Monitor for increased effects.
- CYP3A4 Inducers (e.g., rifampicin, St. John’s Wort): May decrease amlodipine plasma concentrations, potentially reducing its therapeutic efficacy.
- Sildenafil and other PDE5 inhibitors: May potentiate the blood pressure-lowering effect of amlodipine, increasing the risk of symptomatic hypotension.
- Simvastatin: Amlodipine may increase the systemic exposure of simvastatin; the dose of simvastatin should be limited to 20 mg daily when co-administered.
Missed dose
If a dose is missed, it should be taken as soon as it is remembered on the same day. If it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed one, as this could increase the risk of adverse effects like hypotension.
Overdose
Overdose of Norvasc is likely to lead to profound peripheral vasodilation and marked hypotension, possibly resulting in reflex tachycardia. Significant and potentially fatal hypotension can occur. In cases of overdose, active cardiovascular support should be initiated, including frequent monitoring of vital signs and elevation of extremities. Treatment is primarily supportive. Since amlodipine is highly protein-bound, hemodialysis is not likely to be of benefit. Intravenous calcium gluconate may help reverse the effects of calcium channel blockade. The use of vasopressors (e.g., norepinephrine) may be considered for treating hypotension, with attention to circulating fluid volume and urine output.
Storage
Norvasc tablets should be stored at controlled room temperature, 20°C to 25°C (68°F to 77°F), in a dry place, protected from light and moisture. Keep the medication in its original container, tightly closed, and out of reach of children and pets. Do not store in bathrooms or other areas with high humidity. Properly discard any medication that is outdated or no longer needed.
Disclaimer
This information is for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read here. The author and publisher are not responsible for any specific health or allergy needs that may require medical supervision or for any adverse effects resulting from the use of information contained herein.
Reviews
- “As a cardiologist with over 20 years of practice, Norvasc remains a reliable and predictable agent in my antihypertensive arsenal. Its once-daily dosing and consistent 24-hour efficacy support excellent patient adherence. The side effect of peripheral edema can be a limitation for some, but it is often manageable with dose reduction or combination therapy.” – Dr. E. Lawson, MD, Cardiology
- “Clinical trial data consistently demonstrates Norvasc’s robust ability to reduce systolic and diastolic blood pressure. Its long half-life is a significant clinical advantage, preventing early morning BP surges and providing a smooth hemodynamic profile.” – Clinical Pharmacologist Review
- “I was switched to Norvasc 5 mg after another medication caused a persistent cough. My blood pressure has been well-controlled for three years now. I experienced some mild ankle swelling initially, but it subsided after a few weeks. I appreciate only having to take one pill a day.” – Patient J.S., verified user.
- “From a formulary perspective, amlodipine is a cost-effective first-line treatment with a strong evidence base for reducing cardiovascular morbidity. Its widespread availability in generic form improves accessibility for a large patient population.” – Pharmacy & Therapeutics Committee Report.